Alterola Biotech(ABTI)
$0.000.00 (0.00%)
ABTI
Alterola Biotech financials statements
$0.00
At close:0.00 (0.00%)
Alterola Biotech (ABTI) Ratios
10 Followers
Alterola Biotech Ratios
ABTI's free cash flow for Q2 2024 was $-122.16K. For the 2024 fiscal year, ABTI's free cash flow was increased by $0.00 and operating cash flow was $-122.16K. See a summary of the company’s cash flow.
| Ratios | Mar 23 | Mar 22 | Sep 20 | Sep 19 | Sep 18 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.11 | 0.11 | 0.05 | 0.07 | 0.59 |
| Quick Ratio | 0.11 | 0.11 | 0.05 | 0.07 | 0.59 |
| Cash Ratio | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 |
| Solvency Ratio | -0.59 | -5.39 | -0.27 | -0.24 | 0.36 |
| Operating Cash Flow Ratio | -0.49 | 0.04 | 0.00 | 0.00 | -0.23 |
| Short-Term Operating Cash Flow Coverage | -0.82 | 0.27 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -2.04M | $ -1.07M | $ -323.22K | $ -202.71K | $ -55.57K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.11 | 0.01 | 0.00 | 0.00 | 0.39 |
| Debt-to-Equity Ratio | 0.14 | 0.02 | 0.00 | 0.00 | -0.36 |
| Debt-to-Capital Ratio | 0.12 | 0.01 | 0.00 | 0.00 | -0.56 |
| Long-Term Debt-to-Capital Ratio | 0.02 | 0.00 | 0.00 | 0.00 | -0.56 |
| Financial Leverage Ratio | 1.23 | 1.11 | -0.05 | -0.07 | -0.91 |
| Debt Service Coverage Ratio | -1.22 | -39.41 | 0.00 | -1037.96 | -11.66 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -1037.96 | -11.66 |
| Debt to Market Cap | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | -0.83 | -0.02 | 0.00 | 0.00 | -0.16 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 90.89% | 100.00% | 68.46% | 100.00% | 100.00% |
| EBT Per EBIT | 89.46% | 100.00% | 76.03% | 100.10% | 108.58% |
| Return on Assets (ROA) | -12.46% | -53.36% | -1122.97% | -1754.86% | -262.24% |
| Return on Equity (ROE) | -15.28% | -59.23% | 53.06% | 127.62% | 239.47% |
| Return on Capital Employed (ROCE) | -18.51% | -59.23% | 101.95% | 127.50% | 344.10% |
| Return on Invested Capital (ROIC) | -14.98% | -58.35% | 69.80% | 127.50% | -54.61% |
| Return on Tangible Assets | -650.32% | -5057.11% | -1122.97% | -1754.86% | -262.24% |
| Earnings Yield | -4.38% | -3.82% | -0.20% | -0.18% | -0.09% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | 0.00 | 0.00 | 0.00 | -0.00 |
| Free Cash Flow Per Share | -0.00 | 0.00 | 0.00 | 0.00 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | -7.44 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -7.44 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -0.73 | 0.27 | 0.00 | 0.00 | -1.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -3.35% | 0.03% | 0.00% | 0.00% | -0.01% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -22.84 | -26.18 | -488.74 | -549.70 | -1086.08 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.49 | 15.50 | -259.34 | -701.53 | -2600.85 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -29.87 | 3819.97 | 0.00 | 0.00 | -7244.19 |
| Price-to-Operating Cash Flow Ratio | -33.89 | 3819.97 | 0.00 | 0.00 | -7244.19 |
| Price-to-Earnings Growth (PEG) Ratio | 0.30 | -0.06 | 15.36 | -6.60 | -15.21 |
| Enterprise Value Multiple | -21.59 | -26.19 | -334.62 | -550.22 | -1179.38 |
| Enterprise Value | 36.64M | 169.49M | 83.82M | 142.21M | 144.54M |
| EV to EBITDA | -21.59 | -26.19 | -334.62 | -550.22 | -1179.38 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -31.06 | 3822.24 | 0.00 | 0.00 | -7245.19 |
| EV to Operating Cash Flow | -35.24 | 3822.24 | 0.00 | 0.00 | -7245.19 |
| Tangible Book Value Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Shareholders’ Equity Per Share | 0.01 | 0.01 | -0.00 | -0.00 | -0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.09 | 0.00 | 0.32 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | -0.01 | -0.00 | -0.00 | -0.00 |
| Tax Burden | 0.91 | 1.00 | 0.68 | 1.00 | 1.00 |
| Interest Burden | 0.89 | 0.00 | 0.76 | 0.00 | 0.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.60 | -0.01 | 0.00 | 0.00 | 0.15 |
Currency in USD

